A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

Completed

Conditions studied: Metastatic Colorectal Cancer (mCRC)

In brief

The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.

Key facts

Study ID

NCT05420909

Run by

Bristol-Myers Squibb

People needed

124

Starts

2019-01-28

Expected to finish

2019-04-01

Last updated by the study team

2022-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by:
• Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x)
• Pathology consistent with CRC
• At least two documented clinical visits on or after January 1, 2013
• Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013
• Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR)
• Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date
• Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study

You may not qualify if…

• Participants <18 years of age at index date
• Participants who received clinical trial drug during the prior or post periods

Where it is running

• Local Institution — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.